{"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"100"},{"groupId":"BG003","value":"51"},{"groupId":"BG004","value":"294"}],"units":"Participants"}],"groups":[{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"BG000","title":"Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"BG001","title":"Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"BG002","title":"Cohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant"},{"description":"Four doses of nivolumab flat dose 240 mg IV were administered every 2 weeks (monotherapy phase), followed by 12 doses of the combination of AVD (adriamycin/ doxorubicin 25 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2) chemotherapy and nivolumab flat dose 240 mg IV for 6 cycles (combination phase).","id":"BG003","title":"Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.54","value":"36.3"},{"groupId":"BG001","spread":"13.00","value":"38.7"},{"groupId":"BG002","spread":"12.41","value":"36.1"},{"groupId":"BG003","spread":"16.88","value":"39.0"},{"groupId":"BG004","spread":"13.47","value":"37.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"All treated participants","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"121"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"173"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"40"},{"groupId":"BG004","value":"189"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"100"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"86"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"256"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"14"}]}],"title":"Black or African"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"11"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"11"}]}],"title":"Other"}],"paramType":"NUMBER","populationDescription":"All treated particpants","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}